UK markets closed
  • NIKKEI 225

    27,131.34
    -457.03 (-1.66%)
     
  • HANG SENG

    24,243.61
    -412.85 (-1.67%)
     
  • CRUDE OIL

    85.16
    -0.44 (-0.51%)
     
  • GOLD FUTURES

    1,847.80
    -4.70 (-0.25%)
     
  • DOW

    34,297.73
    -66.77 (-0.19%)
     
  • BTC-GBP

    27,217.43
    +67.28 (+0.25%)
     
  • CMC Crypto 200

    831.82
    +11.23 (+1.37%)
     
  • ^IXIC

    13,539.29
    -315.83 (-2.28%)
     
  • ^FTAS

    4,139.47
    +40.31 (+0.98%)
     

ZYMERGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Zymergen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ZY

NEW YORK, December 04, 2021--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymergen Inc. (NASDAQ: ZY) on behalf of long-term stockholders following a class action complaint that was filed against Sequential on August 4, 2021. Our investigation concerns whether the board of directors of Sequential have breached their fiduciary duties to the company.

The complaint alleges that the Registration Statement was materially false and misleading and omitted to state material adverse facts. Specifically, Defendants failed to disclose to investors: (1) that, during the qualification process for Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers’ processes; (2) that, though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) that, as a result, the Company overestimated demand for its products; (4) that, as a result of the foregoing, the Company’s product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

If you are a long-term stockholder of Zymergen, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra B. Raymond by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005596/en/

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting